Human TRAIL R4/TNFRSF10D MAb (Clone 104918) (500 UG)【科瑞奥博】

产品中心

当前位置：首页>产品中心

Human TRAIL R4/TNFRSF10D MAb (Clone 104918) (500 UG)

货号： MAB633 基本售价： 5026.6 元规格： 500 ug

产品信息

概述
货号	MAB633
描述	For ELISA the Antibody Pairs information：Capture antibody：MAB633；Detection antibody：BAF633; and protein: 633-TR-100
别名	CD264 antigen; CD264; DcR2; DCR2decoy with truncated death domain; Decoy receptor 2; TNF receptor-related receptor for TRAIL; TNF-related apoptosis-inducing ligand receptor 4; TNFRSF10D; TRAIL-R4; TRAILR4TRAIL receptor 4; TRUNDDTRAIL receptor with a truncated death domain; tumor necrosis factor receptor superfamily member 10D; tumor necrosis factor receptor superfamily, member 10d, decoy with truncateddeath domain
全称	TRAIL Receptor 4
反应种属	Human
应用	Western Blot,Flow Cytometry,CyTOF-ready,ELISA Capture (Matched Antibody Pair),ELISA Detection (Matched Antibody Pair),ELISA Standard ,Neutralization
目标/特异性	Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, TRAIL R3, rhTRAIL, rhTNF‑ alpha, and rhTNF-beta is observed.
使用方法	Western Blot: 1 µg/mL Flow Cytometry: 2.5 µg/10⁶cells ELISA Capture (Matched Antibody Pair): 2-8 µg/mL ELISA Detection (Matched Antibody Pair): 0.1-0.4 µg/mL ELISA Standard : Neutralization: Measured by its ability to neutralize TRAIL R4/TNFRSF10D-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND₅₀) is typically 0.04-0.2 µg/mL in the presence of 30 ng/mL Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera, 20 ng/mL of Recombinant Human TRAIL/TNFSF10, and 1 µg/mL actinomycin D.
来源	Monoclonal Mouse IgG₁ Clone # 104918
产品组分

性能
供应商	R&D Systems
Entrez Gene IDs	8793 (Human)
应用文献
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. Authors: Neumann S, Hasenauer J, Pollak N, Scheurich P J Biol Chem, 2014;289(23):16576-87. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther., 2012;19(9):652-8. Species: Human Sample Type: Whole Cells Application: Flow Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). Authors: Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P J. Cell. Physiol., 2010;222(2):357-64. Species: Human Sample Type: Whole Cells Application: Flow Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G Blood, 2009;114(18):3854-63. Species: Human Sample Type: Whole Cells Application: Flow P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Authors: Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC Oncogene, 2008;27(30):4161-71. Species: Human Sample Type: Whole Cells Application: Flow Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Authors: Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, DAurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G Stem Cells, 2008;26(11):2955-63. Species: Human Sample Type: Whole Cells Application: Flow Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. Authors: Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C J. Cell. Biochem., 2008;104(2):595-605. Species: Human Sample Type: Whole Cells Application: Flow Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Authors: Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK Mol. Cancer Ther., 2008;7(8):2328-38. Species: Human Sample Type: Whole Cells Application: Flow A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Authors: Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M Cell Death Differ., 2008;15(4):718-729. Species: Human Sample Type: Whole Cells Application: Flow Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM Mol. Cancer Ther., 2007;6(12):3219-28. Species: Human Sample Type: Whole Cells Application: Flow Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. Authors: Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, Sterry W, Eberle J J. Invest. Dermatol., 2007;127(10):2425-37. Species: Human Sample Type: Whole Cells Application: Flow HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Authors: Singh TR, Shankar S, Srivastava RK Oncogene, 2005;24(29):4609-23. Species: Human Sample Type: Whole Cells Application: Flow
纯化方式	Protein A or G purified from ascites
免疫原	Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D Ala56-His211 Accession # Q9UBN6
内毒素水平	<0.10 EU per 1 μg of the antibody by the LAL method.
生物活性	Human
标记	Unconjugated
溶解方法	Reconstitute at 0.5 mg/mL in sterile PBS.
背景	Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type I, TNF R family transmembrane protein, which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL R4 is designated as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.
运输条件	Blue Ice
存放说明	-20℃
参考文献	Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559. Pan, G. et al. (1998) FEBS lett 424:41. Marsters, S.A. et al. (1997) Cur. Biol. 7:1003. Degli-Esposti, M.A. et al. (1997) Immunity 7:813.

参考图片

TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody. In the presence of the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (30 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633). The ND₅₀ is typically 0.04-0.2 µg/mL.